vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and MFA FINANCIAL, INC. (MFA). Click either name above to swap in a different company.
MFA FINANCIAL, INC. is the larger business by last-quarter revenue ($55.5M vs $34.1M, roughly 1.6× Karyopharm Therapeutics Inc.). On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs 9.2%). Over the past eight quarters, MFA FINANCIAL, INC.'s revenue compounded faster (7.7% CAGR vs 1.4%).
MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.
KPTI vs MFA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $55.5M |
| Net Profit | $-102.2M | — |
| Gross Margin | — | — |
| Operating Margin | -52.4% | 97.9% |
| Net Margin | -299.9% | — |
| Revenue YoY | 11.6% | 9.2% |
| Net Profit YoY | -232.0% | — |
| EPS (diluted) | $-7.02 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $55.5M | ||
| Q3 25 | $44.0M | $56.8M | ||
| Q2 25 | $37.9M | $61.3M | ||
| Q1 25 | $30.0M | $57.5M | ||
| Q4 24 | $30.5M | $50.8M | ||
| Q3 24 | $38.8M | $50.6M | ||
| Q2 24 | $42.8M | $53.5M | ||
| Q1 24 | $33.1M | $47.8M |
| Q4 25 | $-102.2M | — | ||
| Q3 25 | $-33.1M | $48.1M | ||
| Q2 25 | $-37.3M | $33.2M | ||
| Q1 25 | $-23.5M | $41.2M | ||
| Q4 24 | $-30.8M | — | ||
| Q3 24 | $-32.1M | $48.2M | ||
| Q2 24 | $23.8M | $41.9M | ||
| Q1 24 | $-37.4M | $23.2M |
| Q4 25 | -52.4% | 97.9% | ||
| Q3 25 | -34.6% | 84.5% | ||
| Q2 25 | -64.3% | 54.5% | ||
| Q1 25 | -110.8% | 70.0% | ||
| Q4 24 | -102.4% | 6.8% | ||
| Q3 24 | -67.8% | 98.2% | ||
| Q2 24 | -65.7% | 79.1% | ||
| Q1 24 | -101.9% | 50.7% |
| Q4 25 | -299.9% | — | ||
| Q3 25 | -75.2% | 84.7% | ||
| Q2 25 | -98.2% | 54.2% | ||
| Q1 25 | -78.2% | 71.6% | ||
| Q4 24 | -100.8% | — | ||
| Q3 24 | -82.7% | 95.2% | ||
| Q2 24 | 55.6% | 78.4% | ||
| Q1 24 | -112.8% | 48.5% |
| Q4 25 | $-7.02 | $0.43 | ||
| Q3 25 | $-3.82 | $0.35 | ||
| Q2 25 | $-4.32 | $0.21 | ||
| Q1 25 | $-2.77 | $0.31 | ||
| Q4 24 | $-2.33 | $-0.01 | ||
| Q3 24 | $-3.85 | $0.37 | ||
| Q2 24 | $-2.97 | $0.32 | ||
| Q1 24 | $-4.85 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $213.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $1.8B |
| Total Assets | $108.4M | $13.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $213.2M | ||
| Q3 25 | $37.7M | $305.2M | ||
| Q2 25 | $38.7M | $275.7M | ||
| Q1 25 | $38.8M | $253.7M | ||
| Q4 24 | $62.5M | $338.9M | ||
| Q3 24 | $72.8M | $305.6M | ||
| Q2 24 | $84.8M | $289.4M | ||
| Q1 24 | $30.6M | $306.3M |
| Q4 25 | $-292.9M | $1.8B | ||
| Q3 25 | $-269.3M | $1.8B | ||
| Q2 25 | $-238.9M | $1.8B | ||
| Q1 25 | $-205.9M | $1.8B | ||
| Q4 24 | $-186.0M | $1.8B | ||
| Q3 24 | $-159.6M | $1.9B | ||
| Q2 24 | $-132.1M | $1.9B | ||
| Q1 24 | $-169.0M | $1.9B |
| Q4 25 | $108.4M | $13.0B | ||
| Q3 25 | $96.2M | $12.1B | ||
| Q2 25 | $104.9M | $11.7B | ||
| Q1 25 | $127.7M | $11.5B | ||
| Q4 24 | $164.4M | $11.4B | ||
| Q3 24 | $189.5M | $11.2B | ||
| Q2 24 | $214.0M | $11.1B | ||
| Q1 24 | $204.5M | $10.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $76.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $76.2M | ||
| Q3 25 | $-5.9M | $14.7M | ||
| Q2 25 | $-18.7M | $38.5M | ||
| Q1 25 | $-39.0M | $-14.6M | ||
| Q4 24 | $-25.8M | $200.1M | ||
| Q3 24 | $-19.5M | $-11.3M | ||
| Q2 24 | $-38.5M | $46.5M | ||
| Q1 24 | $-43.7M | $53.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-25.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-43.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -84.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -132.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | -0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.23× | ||
| Q2 24 | -1.62× | 1.11× | ||
| Q1 24 | — | 2.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
MFA
Segment breakdown not available.
